Metabolic Syndrome Risk Associated with Atypical Antipsychotic Medication: A Case Report

• Main Authors: Julaeha, -, Umi Athiyah, -, Josephine P Ayuningtyas, -, Verra Yuliana, -, Andi Hermansyah, -
• Format: Article PeerReviewed
• Language: English; English; English; English
• Published: Society of Pharmaceutical Technocrats 2021
• Subjects: R Medicine; RS Pharmacy and materia medica; RS1-441 Pharmacy and materia medica; RS200-201 Pharmaceutical dosage forms
• Online Access: https://repository.unair.ac.id/124451/1/Bukti%20Artikel%20C-24.pdf; https://repository.unair.ac.id/124451/4/Bukti%20Validasi%20dan%20Penilaian%20Karil%20C-24.pdf; https://repository.unair.ac.id/124451/3/Bukti%20Similarity%20C-24.pdf; https://repository.unair.ac.id/124451/2/Bukti%20Korespondensi%20C-24.pdf; https://repository.unair.ac.id/124451/; https://jddtonline.info/index.php/jddt/article/view/4680; https://doi.org/10.22270/jddt.v11i1.4680
• Institution: Universitas Airlangga

People with schizophrenia are vulnerable group suffer from metabolic syndrome events. Atypical antipsychotics associated with weight gain, insulin resistance, and profile lipid abnormalities. The present case was 32-year-old man schizophrenia outpatient had experienced metabolic syndrome side effect...